1.
Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers. Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA.
Neurotherapeutics. 2022 Jun 6. doi: 10.1007/s13311-022-01252-5. Online ahead of print.
PMID: 35668317
2.
Thinking outside the box: non-canonical targets in multiple sclerosis. Bierhansl L, Hartung HP, Aktas O, Ruck T, Roden M, Meuth SG.
Nat Rev Drug Discov. 2022 Jun 6. doi: 10.1038/s41573-022-00477-5. Online ahead of print.
PMID: 35668103 Review.
3.
Susceptibility source separation from gradient echo data using magnitude decay modeling. Dimov AV, Nguyen TD, Gillen KM, Marcille M, Spincemaille P, Pitt D, Gauthier SA, Wang Y.
J Neuroimaging. 2022 Jun 6. doi: 10.1111/jon.13014. Online ahead of print.
PMID: 35668022
4.
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies. Freedman MS, Pozzilli C, Havrdova EK, Lemle A, Burcklen M, Larbalestier A, Hennessy B, Sidorenko T, Vaclavkova A, Olsson T; onbehalf of Ponesimod Phase II Study Group.
Neurology. 2022 Jun 6:10.1212/WNL.0000000000200606. doi: 10.1212/WNL.0000000000200606. Online ahead of print.
PMID: 35667837
5.
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis. Versteegh MM, Huygens SA, Wokke BWH, Smolders J.
Value Health. 2022 Jun;25(6):984-991. doi: 10.1016/j.jval.2021.11.1363. Epub 2021 Dec 15.
PMID: 35667786
6.
Fulminant multiple sclerosis in a 36-year-old man. Zaeem Z, Emery D, Blevins G.
CMAJ. 2022 Jun 6;194(22):E776. doi: 10.1503/cmaj.211807.
PMID: 35667665 No abstract available.
7.
Aberrant Neural Activity in Prefrontal Pyramidal Neurons Lacking TDP-43 Precedes Neuron loss. Liang B, Thapa R, Zhang G, Moffitt C, Zhang Y, Zhang L, Johnston A, Ruby HP, Barbera G, Wong PC, Zhang Z, Chen R, Lin DT, Li Y.
Prog Neurobiol. 2022 Jun 3:102297. doi: 10.1016/j.pneurobio.2022.102297. Online ahead of print.
PMID: 35667630
8.
Capturing cognitive changes in multiple sclerosis by performance-based functional and virtual reality assessments. Hsu WY, Goverover Y, Bove RM.
Ann Phys Rehabil Med. 2022 Jun 3:101677. doi: 10.1016/j.rehab.2022.101677. Online ahead of print.
PMID: 35667625 Review.
9.
Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine. Brill L, Rechtman A, Shifrin A, Rozenberg A, Afanasiev S, Zveik O, Haham N, Levin N, Vaknin-Dembinsky A.
Mult Scler Relat Disord. 2022 May 10;63:103863. doi: 10.1016/j.msard.2022.103863. Online ahead of print.
PMID: 35667316
10.
Multiple sclerosis incidence: A systematic review of change over time by geographical region. Lane J, Ng HS, Poyser C, Lucas RM, Tremlett H.
Mult Scler Relat Disord. 2022 May 29;63:103932. doi: 10.1016/j.msard.2022.103932. Online ahead of print.
PMID: 35667315 Review.
11.
Physical activity participation in Australians with multiple sclerosis: associations with geographical remoteness. Learmonth YC, Heritage B, Marck CH, Chen J, van der Mei I.
Disabil Rehabil. 2022 Jun 6:1-6. doi: 10.1080/09638288.2022.2082564. Online ahead of print.
PMID: 35666818
12.
Development of the SPUR tool: a profiling instrument for patient treatment behavior. Tugaut B, Shah S, Dolgin K, Rebibo Seror H, Arnould B, Laporte ME, Lee A, Nabec L, Kayyali R, Wells J, Piette JD, Hubert G.
J Patient Rep Outcomes. 2022 Jun 6;6(1):61. doi: 10.1186/s41687-022-00470-x.
PMID: 35666405
13.
Oncostatin M triggers brain inflammation by compromising blood-brain barrier integrity. Hermans D, Houben E, Baeten P, Slaets H, Janssens K, Hoeks C, Hosseinkhani B, Duran G, Bormans S, Gowing E, Hoornaert C, Beckers L, Fung WK, Schroten H, Ishikawa H, Fraussen J, Thoelen R, de Vries HE, Kooij G, Zandee S, Prat A, Hellings N, Broux B.
Acta Neuropathol. 2022 Jun 6. doi: 10.1007/s00401-022-02445-0. Online ahead of print.
PMID: 35666306
14.
Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action. Muñoz-Jurado A, Escribano BM, Caballero-Villarraso J, Galván A, Agüera E, Santamaría A, Túnez I.
Inflammopharmacology. 2022 Jun 5. doi: 10.1007/s10787-022-01011-0. Online ahead of print.
PMID: 35665873 Review.
15.
Incidence and safety outcomes associated with active stone removal procedures (ASRP): a comparison between neurological and non-neurological patients using the French National Health Data Base. Beraud F, Clément G, Lenne X, Biardeau X.
World J Urol. 2022 Jun 4. doi: 10.1007/s00345-022-04054-8. Online ahead of print.
PMID: 35665842
16.
Association of multiple sclerosis with risk of mortality among a nationally representative sample of adults in the United States. Titcomb TJ, Bao W, Du Y, Liu B, Snetselaar LG, Wahls TL.
Mult Scler J Exp Transl Clin. 2022 May 30;8(2):20552173221104009. doi: 10.1177/20552173221104009. eCollection 2022 Apr-Jun.
PMID: 35665135 Free PMC article.
17.
Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha. Kiriacos CJ, Khedr MR, Tadros M, Youness RA.
Front Oncol. 2022 May 18;12:837408. doi: 10.3389/fonc.2022.837408. eCollection 2022.
PMID: 35664773 Free PMC article. Review.
18.
Surgical timing for primary encapsulating peritoneal sclerosis: A case report and review of literature. Deng P, Xiong LX, He P, Hu JH, Zou QX, Le SL, Wen SL.
World J Gastrointest Surg. 2022 Apr 27;14(4):352-361. doi: 10.4240/wjgs.v14.i4.352.
PMID: 35664367 Free PMC article.
19.
Perception of COVID-19 Pandemic by Brazilian People With Parkinson’s Disease and Multiple Sclerosis. Simieli L, Santinelli FB, Costa EC, Kuroda MH, Oliveira LR, Penedo T, Pilon J, Silveira APB, Assis ISA, Tardelli E, Okamoto E, Barbieri FA.
Front Psychol. 2022 May 19;13:718313. doi: 10.3389/fpsyg.2022.718313. eCollection 2022.
PMID: 35664184 Free PMC article.
20.
Hyper-Reflecting Foci in Multiple Sclerosis Retina Associate With Macrophage/Microglia-Derived Cytokines in Cerebrospinal Fluid. Puthenparampil M, Torresin T, Franciotta S, Marin A, De Napoli F, Mauceri VA, Miante S, Pilotto E, Midena E, Gallo P.
Front Immunol. 2022 May 19;13:852183. doi: 10.3389/fimmu.2022.852183. eCollection 2022.
PMID: 35664007 Free PMC article.
21.
RGMa Participates in the Blood-Brain Barrier Dysfunction Through BMP/BMPR/YAP Signaling in Multiple Sclerosis. Zhang L, Tang S, Ma Y, Liu J, Monnier P, Li H, Zhang R, Yu G, Zhang M, Li Y, Feng J, Qin X.
Front Immunol. 2022 May 18;13:861486. doi: 10.3389/fimmu.2022.861486. eCollection 2022.
PMID: 35664003 Free PMC article.
22.
Altered Cellular Immunity and Differentially Expressed Immune-Related Genes in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Tu J, Jin J, Chen X, Sun L, Cai Z.
Front Immunol. 2022 May 18;13:868983. doi: 10.3389/fimmu.2022.868983. eCollection 2022.
PMID: 35663995 Free PMC article.
23.
A rare presentation of multiple sclerosis: Schilder’s disease. Taoussi R, Khattab H, Sakhy Y, Merzem A, Belgadir H, Amriss O, Moussali N, Benna NE.
Radiol Case Rep. 2022 May 29;17(8):2661-2664. doi: 10.1016/j.radcr.2022.04.048. eCollection 2022 Aug.
PMID: 35663822 Free PMC article.
24.
Coupling cognitive and brainstem dysfunction in multiple sclerosis-related chronic neuropathic limb pain. Foley P, Kong Y, Dirvanskiene R, Valdes-Hernandez M, Bastiani M, Murnane J, Sellar R, Roberts N, Pernet C, Weir C, Bak T, Colvin L, Chandran S, Fallon M, Tracey I.
Brain Commun. 2022 May 17;4(3):fcac124. doi: 10.1093/braincomms/fcac124. eCollection 2022.
PMID: 35663383 Free PMC article.
25.
Preventing Axonal Sodium Overload or Mitochondrial Calcium Uptake Protects Axonal Mitochondria from Oxidative Stress-Induced Alterations. Ulshöfer R, Bros H, Hauser AE, Niesner RA, Paul F, Malla B, Infante-Duarte C.
Oxid Med Cell Longev. 2022 May 24;2022:6125711. doi: 10.1155/2022/6125711. eCollection 2022.
PMID: 35663200 Free PMC article.
26.
New-onset pemphigus foliaceus following SARS-CoV-2 infection and unmasking multiple sclerosis: A case report. Mohaghegh F, Hatami P, Refaghat A, Mehdizadeh M, Aryanian Z, Mohandesi NA, Afshar ZM.
Clin Case Rep. 2022 Jun 3;10(6):e05910. doi: 10.1002/ccr3.5910. eCollection 2022 Jun.
PMID: 35662780 Free PMC article.
27.
Effects of Deep Brain Stimulation on Lower Urinary Tract Function in Neurological Patients. Sartori AM, Kiss B, Mordasini L, Pollo C, Schüpbach M, Burkhard FC, Schwab ME, Kaelin-Lang A, Kessler TM.
Eur Urol Focus. 2022 May 31:S2405-4569(22)00127-4. doi: 10.1016/j.euf.2022.05.004. Online ahead of print.
PMID: 35662503
28.
NR4A1 agonist cytosporone B attenuates neuroinflammation in a mouse model of multiple sclerosis. Yu HZ, Zhu BQ, Zhu L, Li S, Wang LM.
Neural Regen Res. 2022 Dec;17(12):2765-2770. doi: 10.4103/1673-5374.339492.
PMID: 35662227
29.
Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases. Wang Q, Song LJ, Ding ZB, Chai Z, Yu JZ, Xiao BG, Ma CG.
Neural Regen Res. 2022 Dec;17(12):2623-2631. doi: 10.4103/1673-5374.335827.
PMID: 35662192 Review.
30.
The “mitochondrial stress responses”: the “Dr. Jekyll and Mr. Hyde” of neuronal disorders. Patergnani S, Morciano G, Carinci M, Leo S, Pinton P, Rimessi A.
Neural Regen Res. 2022 Dec;17(12):2563-2575. doi: 10.4103/1673-5374.339473.
PMID: 35662183 Review.
31.
Random noise stimulation in the treatment of patients with neurological disorders. Herrera-Murillo MA, Treviño M, Manjarrez E.
Neural Regen Res. 2022 Dec;17(12):2557-2562. doi: 10.4103/1673-5374.339474.
PMID: 35662182 Review.
32.
Cadherin-11 and its role in tissue fibrosis. Chavula T, To S, Agarwal SK.
Cells Tissues Organs. 2022 Jun 3. doi: 10.1159/000525359. Online ahead of print.
PMID: 35662129 Review.
33.
Repeated lumbar puncture in search of oligoclonal bands – What is the yield? Mermelstein M, Naftali J, Wilf-Yarkoni A, Lotan I, Hellmann MA, Steiner I.
J Neurol Sci. 2022 May 26;439:120298. doi: 10.1016/j.jns.2022.120298. Online ahead of print.
PMID: 35662071
34.
Molecular signaling pathways, pathophysiological features in various organs, and treatment strategies in SARS-CoV2 infection. Rasmi Y, Hatamkhani S, Naderi R, Shokati A, Nayeb Zadeh V, Hosseinzadeh F, Farnamian Y, Jalali L.
Acta Histochem. 2022 May 25;124(5):151908. doi: 10.1016/j.acthis.2022.151908. Online ahead of print.
PMID: 35662001 Review.
35.
Global assessment of characteristics of multiple sclerosis registries; A systematic review. Ezabadi SG, Sahraian MA, Maroufi H, Shahrbaf MA, Eskandarieh S.
Mult Scler Relat Disord. 2022 May 28;63:103928. doi: 10.1016/j.msard.2022.103928. Online ahead of print.
PMID: 35661909 Review.
36.
Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases. Cao B, Luo M, Li J, Lu Y, Chang Y, Chen Z, Li R, Hu B, Lu Z, Qiu W, Shu Y.
J Neuroimmunol. 2022 May 27;369:577900. doi: 10.1016/j.jneuroim.2022.577900. Online ahead of print.
PMID: 35661900
37.
Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Ruck T, Barman S, Schulte-Mecklenbeck A, Pfeuffer S, Steffen F, Nelke C, Schroeter CB, Willison A, Heming M, Müntefering T, Melzer N, Krämer J, Lindner M, Riepenhausen M, Gross CC, Klotz L, Bittner S, Muraro PA, Schneider-Hohendorf T, Schwab N, Meyer Zu Hörste G, Goebels N, Meuth SG, Wiendl H.
Brain. 2022 Jun 3;145(5):1711-1725. doi: 10.1093/brain/awac064.
PMID: 35661859
38.
Nuclear RIPK1 promotes chromatin remodeling to mediate inflammatory response. Li W, Shan B, Zou C, Wang H, Zhang MM, Zhu H, Naito MG, Xu D, Manuel VJ, Mifflin L, Hou Z, Ravits J, Yuan J.
Cell Res. 2022 Jun 3. doi: 10.1038/s41422-022-00673-3. Online ahead of print.
PMID: 35661830
39.
The impact of COVID-19 on people with multiple sclerosis: A comparison of Italian and United States cohorts. Schwartz CE, Rapkin BD, Bonavita S, Bossa M, Buscarinu MC, Grasso MG, Luca M, Nozzolillo A, Nocentini U.
Mult Scler Relat Disord. 2022 May 19;63:103888. doi: 10.1016/j.msard.2022.103888. Online ahead of print.
PMID: 35661570
40.
Relationship between apathy and cognitive dysfunctions in multiple sclerosis: A 4-year prospective longitudinal study. Raimo S, Trojano L, Gaita M, d’Onofrio F, Spitaleri D, Santangelo G.
Mult Scler Relat Disord. 2022 May 28;63:103929. doi: 10.1016/j.msard.2022.103929. Online ahead of print.
PMID: 35661569
41.
Hiding in plain sight: The magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care. Okuda DT, Burgess KW, Cook K, McCreary M, Winkler MD, Moog TM.
Mult Scler Relat Disord. 2022 May 27;63:103920. doi: 10.1016/j.msard.2022.103920. Online ahead of print.
PMID: 35661567
42.
Sick leave and occupational burnout among nurses caring for patients with multiple sclerosis. Saposnik G, Bueno-Gil G, Sempere ÁP, Del Río-Muñoz B, Lendínez-Mesa A, Azanza-Munarriz C, Becerril-Ríos N, Goicochea-Briceño H, Horno R, Sánchez-Franco C, Medrano N, Rodríguez-Antigüedad A, Maurino J.
Mult Scler Relat Disord. 2022 May 28;63:103916. doi: 10.1016/j.msard.2022.103916. Online ahead of print.
PMID: 35661566
43.
Validity and reliability of the 10-item Connor-Davidson Resilience Scale (CD-RISC-10) in a sample of Spanish-speaking patients with Multiple Sclerosis. Broche-Pérez Y, Jiménez-Morales RM, Monasterio-Ramos LO, Bauer J.
Mult Scler Relat Disord. 2022 May 27;63:103914. doi: 10.1016/j.msard.2022.103914. Online ahead of print.
PMID: 35661565
44.
Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic. Li V, Roos I, Monif M, Malpas C, Roberts S, Marriott M, Buzzard K, Nguyen AL, Seery N, Taylor L, Kalincik T, Kilpatrick T.
Mult Scler Relat Disord. 2022 May 27;63:103913. doi: 10.1016/j.msard.2022.103913. Online ahead of print.
PMID: 35661564
45.
Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters. Conte WL, Golzarri-Arroyo L.
Mult Scler Relat Disord. 2022 May 21;63:103905. doi: 10.1016/j.msard.2022.103905. Online ahead of print.
PMID: 35661563
46.
Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis. Knudsen MH, Lindberg U, Frederiksen JL, Vestergaard MB, Simonsen HJ, Varatharaj A, Galea I, Blinkenberg M, Sellebjerg F, Larsson HBW, Cramer SP.
Mult Scler Relat Disord. 2022 May 18;63:103891. doi: 10.1016/j.msard.2022.103891. Online ahead of print.
PMID: 35661562
47.
Magnetic susceptibility anisotropy in normal appearing white matter in multiple sclerosis from single-orientation acquisition. Sibgatulin R, Güllmar D, Deistung A, Enzinger C, Ropele S, Reichenbach JR.
Neuroimage Clin. 2022 May 28;35:103059. doi: 10.1016/j.nicl.2022.103059. Online ahead of print.
PMID: 35661471
48.
Role of artificial intelligence in MS clinical practice. Bonacchi R, Filippi M, Rocca MA.
Neuroimage Clin. 2022 May 28;35:103065. doi: 10.1016/j.nicl.2022.103065. Online ahead of print.
PMID: 35661470
49.
Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications. Spampinato SF, Sortino MA, Salomone S.
Adv Pharmacol. 2022;94:95-139. doi: 10.1016/bs.apha.2022.02.001. Epub 2022 Mar 30.
PMID: 35659378
50.
CEST MRI and MALDI imaging reveal metabolic alterations in the cervical lymph nodes of EAE mice. Thomas AM, Yang E, Smith MD, Chu C, Calabresi PA, Glunde K, van Zijl PCM, Bulte JWM.
J Neuroinflammation. 2022 Jun 3;19(1):130. doi: 10.1186/s12974-022-02493-z.
PMID: 35659311
1.
Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. Lie IA, Kaçar S, Wesnes K, Brouwer I, Kvistad SS, Wergeland S, Holmøy T, Midgard R, Bru A, Edland A, Eikeland R, Gosal S, Harbo HF, Kleveland G, Sørenes YS, Øksendal N, Varhaug KN, Vedeler CA, Barkhof F, Teunissen CE, Bø L, Torkildsen Ø, Myhr KM, Vrenken H.
J Neurol Neurosurg Psychiatry. 2022 Jun 1:jnnp-2021-328568. doi: 10.1136/jnnp-2021-328568. Online ahead of print.
PMID: 35649699
2.
Curcumin-based nanotechnology approaches and therapeutics in restoration of autoimmune diseases. Rahiman N, Nikiforov NG, Kesharwani P, Johnston TP, Sahebkar A.
J Control Release. 2022 May 29:S0168-3659(22)00318-2. doi: 10.1016/j.jconrel.2022.05.046. Online ahead of print.
PMID: 35649486 Review.
3.
Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis. Cole A, Ong VH, Denton CP.
Clin Rev Allergy Immunol. 2022 Jun 1. doi: 10.1007/s12016-022-08945-x. Online ahead of print.
PMID: 35648373 Review.
4.
Bioinformatics approach reveals the critical role of the NOD-like receptor signaling pathway in COVID-19-associated multiple sclerosis syndrome. Qiu D, Zhang D, Yu Z, Jiang Y, Zhu D.
J Neural Transm (Vienna). 2022 Jun 1. doi: 10.1007/s00702-022-02518-0. Online ahead of print.
PMID: 35648256
5.
Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis. Miscioscia A, Puthenparampil M, Miante S, Pengo M, Rinaldi F, Perini P, Gallo P.
J Neurol. 2022 Jun 1. doi: 10.1007/s00415-022-11183-y. Online ahead of print.
PMID: 35648233
6.
Sequence Determinants of TDP-43 Ribonucleoprotein Condensate Formation and Axonal Transport in Neurons. Vishal SS, Wijegunawardana D, Salaikumaran MR, Gopal PP.
Front Cell Dev Biol. 2022 May 12;10:876893. doi: 10.3389/fcell.2022.876893. eCollection 2022.
PMID: 35646935 Free PMC article.
7.
RNA Helicases in Microsatellite Repeat Expansion Disorders and Neurodegeneration. Castelli LM, Benson BC, Huang WP, Lin YH, Hautbergue GM.
Front Genet. 2022 May 12;13:886563. doi: 10.3389/fgene.2022.886563. eCollection 2022.
PMID: 35646086 Free PMC article. Review.
8.
Total Dairy Consumption Is Not Associated With Likelihood of a First Clinical Diagnosis of Central Nervous System Demyelination. Dieu DYR, Dunlop E, Daly A, Lucas RM, Probst Y, Black LJ.
Front Neurol. 2022 May 13;13:888559. doi: 10.3389/fneur.2022.888559. eCollection 2022.
PMID: 35645978 Free PMC article.
9.
Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases. Saab G, Munoz DG, Rotstein DL.
Front Neurol. 2022 May 13;13:863151. doi: 10.3389/fneur.2022.863151. eCollection 2022.
PMID: 35645973 Free PMC article.
10.
Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the “Attikon” Lupus Cohort. Nikolopoulos D, Kitsos D, Papathanasiou M, Kapsala N, Garantziotis P, Pieta A, Gioti O, Grivas A, Voumvourakis K, Boumpas D, Fanouriakis A.
Front Neurol. 2022 May 11;13:889613. doi: 10.3389/fneur.2022.889613. eCollection 2022.
PMID: 35645967 Free PMC article.
11.
Editorial: Autoimmunity and the Brain: Paraneoplastic Neurological Injury and Beyond. Greenlee JE, Carlson NG, Abbatemarco JR, Herdlevær I, Clardy SL, Vedeler CA.
Front Neurol. 2022 May 12;13:900130. doi: 10.3389/fneur.2022.900130. eCollection 2022.
PMID: 35645953 Free PMC article. No abstract available.
12.
Self-reported Reasons for Changes in Performance of Daily Activities During a 2-Year Multidisciplinary Multiple Sclerosis Rehabilitation. Karhula ME, Kanelisto K, Hämäläinen P, Ruutiainen J, Era P, Häkkinen A, Salminen AL.
Int J MS Care. 2022 May-Jun;24(3):110-116. doi: 10.7224/1537-2073.2020-061. Epub 2021 Sep 14.
PMID: 35645629 Free PMC article.
13.
The Impact of COVID-19 on the Lives of Individuals With Multiple Sclerosis: 1 Year Into the Pandemic. Lynch S, Baker S, Hunt S, Thuringer A, Jassam Y, Bruce J.
Int J MS Care. 2022 May-Jun;24(3):139-144. doi: 10.7224/1537-2073.2021-099. Epub 2022 May 24.
PMID: 35645628 Free PMC article.
14.
Motivation for Physical Activity in Adults With Multiple Sclerosis: A Self-determination Theory-Based Approach. McCarty N, Sayer S, Kasser SL.
Int J MS Care. 2022 May-Jun;24(3):117-123. doi: 10.7224/1537-2073.2020-091. Epub 2021 Oct 12.
PMID: 35645627 Free PMC article.
15.
Managing Cognitive Dysfunction in Multiple Sclerosis: A Snapshot of Changes in Screening, Assessment, and Treatment Practices. Gromisch ES, DeLuca J, Benedict RHB, Foley FW.
Int J MS Care. 2022 May-Jun;24(3):104-109. doi: 10.7224/1537-2073.2020-139. Epub 2021 Sep 13.
PMID: 35645626 Free PMC article.
16.
Sleep Quality in Neuromyelitis Optica Spectrum Disorder: A Systematic Review. Eshtiaghi A, Eapen-John D, Zaslavsky K, Vosoughi R, Murray BJ, Margolin E.
Int J MS Care. 2022 May-Jun;24(3):124-131. doi: 10.7224/1537-2073.2021-019. Epub 2021 Aug 18.
PMID: 35645625 Free PMC article.
17.
Effects of Vibration Training on Cognition and Quality of Life in Individuals With Multiple Sclerosis. Yang F, Wen PS, Bethoux F, Zhao Y.
Int J MS Care. 2022 May-Jun;24(3):132-138. doi: 10.7224/1537-2073.2020-095. Epub 2021 Aug 2.
PMID: 35645623 Free PMC article.
18.
Novel Heterozygous Variants in the HLA-DRB1 Gene in a Saudi Family With Early-Onset Familial Multiple Sclerosis: Therapeutic Failure and Success. Algahtani H, Shirah B, Khafaji R, Algahtani S.
Int J MS Care. 2022 May-Jun;24(3):100-103. doi: 10.7224/1537-2073.2020-125. Epub 2021 Oct 5.
PMID: 35645622 Free PMC article.
19.
Histological and Top-Down Proteomic Analyses of the Visual Pathway in the Cuprizone Demyelination Model. Almuslehi MSM, Sen MK, Shortland PJ, Mahns DA, Coorssen JR.
J Mol Neurosci. 2022 May 30. doi: 10.1007/s12031-022-01997-w. Online ahead of print.
PMID: 35644788
20.
Tissue-resident CD8 T cells in central nervous system inflammatory diseases: present at the crime scene and …guilty. Merkler D, Vincenti I, Masson F, Liblau RS.
Curr Opin Immunol. 2022 May 26;77:102211. doi: 10.1016/j.coi.2022.102211. Online ahead of print.
PMID: 35644112 Review.
21.
FRACTAL DIMENSION OF THE BRAIN IN NEURODEGENERATIVE DISEASE AND DEMENTIA: A SYSTEMATIC REVIEW. Ziukelis ET, Mak E, Dounavi ME, Su L, O’Brien J.
Ageing Res Rev. 2022 May 25:101651. doi: 10.1016/j.arr.2022.101651. Online ahead of print.
PMID: 35643264 Review.
22.
Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study. Al-Yafeai Z, Carvajal-González A, Abduljabar H, Arvas M, Patel S, Patel N.
Int J Cardiol. 2022 May 25:S0167-5273(22)00763-X. doi: 10.1016/j.ijcard.2022.05.052. Online ahead of print.
PMID: 35643216
23.
Mutation Screening of TFG in α-Synucleinopathy and Amyotrophic Lateral Sclerosis. Li C, Lin J, Gu X, Hou Y, Liu K, Jiang Q, Ou R, Wei Q, Chen X, Song W, Zhao B, Wu Y, Chen Y, Shang H.
Mov Disord. 2022 May 31. doi: 10.1002/mds.29079. Online ahead of print.
PMID: 35642252
24.
Protocol for the development of a core outcome set for evaluating mixed-diagnosis falls prevention interventions for people with Multiple Sclerosis, Parkinson’s Disease and stroke. O’Malley N, Coote S, Clifford AM.
HRB Open Res. 2022 May 6;4:123. doi: 10.12688/hrbopenres.13459.2. eCollection 2021.
PMID: 35633846 Free PMC article.
1.
Ageing reduces potential for remyelination in multiple sclerosis. Fyfe I.
Nat Rev Neurol. 2022 May 31. doi: 10.1038/s41582-022-00680-3. Online ahead of print.
PMID: 35641684 No abstract available.
2.
Autophagy Modulation in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Shen D, Liu K, Wang H, Wang H.
Clin Exp Immunol. 2022 Feb 16:uxac017. doi: 10.1093/cei/uxac017. Online ahead of print.
PMID: 35641229
3.
Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis. Petrou P, Kassis I, Ginzberg A, Hallimi M, Karussis D.
Stem Cells Transl Med. 2022 Mar 3;11(1):55-58. doi: 10.1093/stcltm/szab017.
PMID: 35641166
4.
Strategies for targeting the P2Y12 receptor in the Central Nervous System. Ma BB, Montgomery AP, Chen B, Kassiou M, Danon JJ.
Bioorg Med Chem Lett. 2022 May 28:128837. doi: 10.1016/j.bmcl.2022.128837. Online ahead of print.
PMID: 35640763 Review.
5.
Ex-Gaussian analysis of simple response time as a measure of information processing speed and the relationship with brain morphometry in multiple sclerosis. Mui M, Ruben RM, Ricker TJ, Dobryakova E, Sandry J.
Mult Scler Relat Disord. 2022 May 17;63:103890. doi: 10.1016/j.msard.2022.103890. Online ahead of print.
PMID: 35640465
6.
Preferences for Disease-Modifying Therapies in Argentina: Cross-Sectional Conjoint Analysis of Patients and Neurologist. Rojas JI, Patrucco L, Alonso R, Lopez PA, Deri N, Pettinicchi JP, Cristiano E, Carnero Contentti E.
Value Health Reg Issues. 2022 May 25;31:93-100. doi: 10.1016/j.vhri.2022.04.001. Online ahead of print.
PMID: 35640464
7.
A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma. Li C, Zhou Y, Xu J, Zhou X, Huang Z, Zeng T, Yang X, Tao L, Gou K, Zhong X, Chen Q, Luo Y, Zhao Y.
Eur J Med Chem. 2022 May 26;238:114489. doi: 10.1016/j.ejmech.2022.114489. Online ahead of print.
PMID: 35640328
8.
Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine. Aikawa NE, Kupa LVK, Silva CA, Saad CGS, Pasoto SG, Yuki EFN, Fusco SRG, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Pereira RMR, Chasin ACS, Shimabuco AY, Luppino-Assad AP, Leon EP, Lopes MH, Antonangelo L, Medeiros-Ribeiro AC, Bonfa E.
Rheumatology (Oxford). 2022 May 26:keac301. doi: 10.1093/rheumatology/keac301. Online ahead of print.
PMID: 35639644
9.
Reporting of “usual care” as the control group in randomized clinical trials of physiotherapy interventions for multiple sclerosis is poor: a systematic review. Paci M, Risaliti F, Pellicciari L.
Neurol Sci. 2022 May 31. doi: 10.1007/s10072-022-06167-9. Online ahead of print.
PMID: 35639218 Review.
10.
The importance of assessing sleep disorders in multiple sclerosis. Kondo J, Morelhão PK, Tufik S, Andersen ML.
Sleep Breath. 2022 May 31. doi: 10.1007/s11325-022-02653-8. Online ahead of print.
PMID: 35639201 No abstract available.
11.
A role for the Epstein-Barr virus in multiple sclerosis aetiology? Hrastelj J, Robertson NP.
J Neurol. 2022 May 31. doi: 10.1007/s00415-022-11177-w. Online ahead of print.
PMID: 35639199 No abstract available.
12.
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, Cree BAC.
J Neurol. 2022 May 31. doi: 10.1007/s00415-022-11166-z. Online ahead of print.
PMID: 35639197
13.
[Multiple sclerosis: 10 key messages]. Stankoff B.
Rev Prat. 2022 Apr;72(4):416.
PMID: 35638987 French. No abstract available.
14.
[Multiple sclerosis: what therapeutic perspectives ?]. Louapre C, Stankoff B, Bodini B.
Rev Prat. 2022 Apr;72(4):410-415.
PMID: 35638986 French.
15.
[Immunizations for people with multiple sclerosis]. Lebrun-Frénay C.
Rev Prat. 2022 Apr;72(4):407-409.
PMID: 35638985 French. No abstract available.
16.
[Psychological aspects in multiple sclerosis]. Viret AC.
Rev Prat. 2022 Apr;72(4):405-406.
PMID: 35638984 French. No abstract available.
17.
[Current management of multiple sclerosis]. Maarouf A, Audoin B, Pelletier J.
Rev Prat. 2022 Apr;72(4):399-404.
PMID: 35638983 French.
18.
[Multiple sclerosis and pregnancy]. Maillart É, Papeix C.
Rev Prat. 2022 Apr;72(4):394-398.
PMID: 35638982 French.
19.
[Differential diagnoses of multiple sclerosis]. Marignier R.
Rev Prat. 2022 Apr;72(4):392-393.
PMID: 35638981 French. No abstract available.
20.
[“Diagnosis of multiple sclerosis, diagnostic criteria and contribution of imaging to diagnosis”]. Vukusic S, Androdias G.
Rev Prat. 2022 Apr;72(4):387-391.
PMID: 35638980 French.
21.
[Epidemiology of multiple sclerosis]. Magy L.
Rev Prat. 2022 Apr;72(4):385-386.
PMID: 35638979 French. No abstract available.
22.
[Clinical forms and pathophysiology of multiple sclerosis]. Shah S, Laplaud DA.
Rev Prat. 2022 Apr;72(4):380-384.
PMID: 35638978 French.
23.
Anlotinib attenuates experimental autoimmune encephalomyelitis mice model of multiple sclerosis via modulating the differentiation of Th17 and Treg cells. Zhu H, Li G, Yin J, Zhang H, Da Y, Li L.
Immunopharmacol Immunotoxicol. 2022 May 31:1-9. doi: 10.1080/08923973.2022.2071722. Online ahead of print.
PMID: 35638564
24.
The 3-m backward walk test: reliability and validity in ambulant people with multiple sclerosis. Söke F, Demirkaya Ş, Yavuz N, Gülşen EÖ, Tunca Ö, Gülşen Ç, Karakoç S, Koçer B, Aydin F, Yücesan C.
Int J Rehabil Res. 2022 May 31:MRR.0000000000000530. doi: 10.1097/MRR.0000000000000530. Online ahead of print.
PMID: 35638202
25.
Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M.
Patient Prefer Adherence. 2022 May 24;16:1307-1319. doi: 10.2147/PPA.S221882. eCollection 2022.
PMID: 35637684 Free PMC article. Review.
26.
Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review. Chatterjee T, Roy M, Lin RC, Almoujahed MO, Ahmad S.
IDCases. 2022 May 20;28:e01514. doi: 10.1016/j.idcr.2022.e01514. eCollection 2022.
PMID: 35637642 Free PMC article.
27.
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, Leray E.
BMC Med Res Methodol. 2022 May 30;22(1):155. doi: 10.1186/s12874-022-01623-8.
PMID: 35637426
28.
Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies. Wallach AI, Schiebel M, Picone MA.
Mult Scler Relat Disord. 2022 May 6;63:103856. doi: 10.1016/j.msard.2022.103856. Online ahead of print.
PMID: 35636275
29.
Has the pandemic changed treatment strategy in multiple sclerosis? Bsteh G, Riedl K, Krajnc N, Kornek B, Leutmezer F, Macher S, Rommer P, Zulehner G, Berger T; VMSD study group.
Mult Scler Relat Disord. 2022 May 23;63:103912. doi: 10.1016/j.msard.2022.103912. Online ahead of print.
PMID: 35636274
30.
Associations between diet quality and depression, anxiety, and fatigue in multiple sclerosis. Saul A, Taylor BV, Blizzard L, Simpson-Yap S, Oddy WH, Probst YC, Black LJ, Ponsonby AL, Broadley SA, Lechner-Scott J, van der Mei I.
Mult Scler Relat Disord. 2022 May 23;63:103910. doi: 10.1016/j.msard.2022.103910. Online ahead of print.
PMID: 35636273
31.
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS). Dobson R, Craner M, Waddingham E, Miller A, Pindoria J, Cavey A, Blain C, De Luca G, Evangelou N, Ford H, Gallagher P, George K, Geraldes Ramos Dias R, Harman P, Hobart J, King T, Linighan R, MacDougall N, Marta M, Mitchell S, Nicholas R, Rog D, Scalfari A, Scolding N, Webb S, White S, Wilton J, Young C, Matthews PM.
Mult Scler Relat Disord. 2022 May 20;63:103894. doi: 10.1016/j.msard.2022.103894. Online ahead of print.
PMID: 35636271
32.
Do device-measured physical activity and sedentary behavior differ by depression symptom status in persons with multiple sclerosis? Jones CD, Jeng B, Silic P, Motl RW.
Mult Scler Relat Disord. 2022 May 14;63:103889. doi: 10.1016/j.msard.2022.103889. Online ahead of print.
PMID: 35636270
33.
Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with multiple sclerosis. Borrelli S, Mathias A, Goff GL, Pasquier RD, Théaudin M, Pot C.
Mult Scler Relat Disord. 2022 May 15;63:103887. doi: 10.1016/j.msard.2022.103887. Online ahead of print.
PMID: 35636269
34.
The Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR)–Critical review facing the 20 anniversary. Heesen C, Magyari M, Stellmann JP, Lederer C, Giovannoni G, Scalfari A, Daumer M.
Mult Scler Relat Disord. 2022 May 16;63:103885. doi: 10.1016/j.msard.2022.103885. Online ahead of print.
PMID: 35636268 Review.
35.
Clinical outcomes of partial sensory root rhizotomy on patients with recurrence of multiple sclerosing trigeminal neuralgia after percutaneous balloon compression. Li Y, Zhang G, Zhang J, Cheng Z, Lan Y.
Mult Scler Relat Disord. 2022 May 16;63:103883. doi: 10.1016/j.msard.2022.103883. Online ahead of print.
PMID: 35636267
36.
Burden of multiple sclerosis: impact on the patient, family and society. Sarhan AA, El-Sharkawy KA, Mahmoudy AM, Hashim NA.
Mult Scler Relat Disord. 2022 May 11;63:103864. doi: 10.1016/j.msard.2022.103864. Online ahead of print.
PMID: 35636266
37.
Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis. Thompson B, Moghaddam N, Evangelou N, Baufeldt A, das Nair R.
Mult Scler Relat Disord. 2022 May 10;63:103862. doi: 10.1016/j.msard.2022.103862. Online ahead of print.
PMID: 35636265 Review.
38.
A Stably Established Two-point Injection of Lysophosphatidylcholine-induced Focal Demyelination Model in Mice. Pang XW, Chen M, Chu YH, Tang Y, Qin C, Tian DS.
J Vis Exp. 2022 May 11;(183). doi: 10.3791/64059.
PMID: 35635470
39.
Frequency of neuropathic pain and its effects on rehabilitation outcomes, balance function and quality of life among people with traumatic spinal cord injury. Khan MI, Arsh A, Ali I, Afridi AK.
Pak J Med Sci. 2022 Mar-Apr;38(4Part-II):888-892. doi: 10.12669/pjms.38.4.4681.
PMID: 35634589 Free PMC article.
40.
Guanidinoacetic Acid as a Nutritional Adjuvant to Multiple Sclerosis Therapy. Ostojic SM.
Front Hum Neurosci. 2022 May 12;16:871535. doi: 10.3389/fnhum.2022.871535. eCollection 2022.
PMID: 35634212 Free PMC article. Review.
41.
Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis. Marrie RA, Dolovich C, Cutter GR, Fox RJ, Salter A.
Mult Scler J Exp Transl Clin. 2022 May 22;8(2):20552173221102067. doi: 10.1177/20552173221102067. eCollection 2022 Apr-Jun.
PMID: 35634013 Free PMC article.
42.
Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis. Silveira SL, Jeng B, Cutter G, Motl RW.
Mult Scler J Exp Transl Clin. 2022 May 25;8(2):20552173221097580. doi: 10.1177/20552173221097580. eCollection 2022 Apr-Jun.
PMID: 35634012 Free PMC article.
43.
Predictors of positive outcomes following resistive inspiratory muscle training in non-ambulatory persons with advanced multiple sclerosis. Huang MH, Doyle L, Burnham A, Fry DK, Shea K.
Mult Scler J Exp Transl Clin. 2022 May 23;8(2):20552173211058862. doi: 10.1177/20552173211058862. eCollection 2022 Apr-Jun.
PMID: 35634011 Free PMC article.
44.
Association of depression and obesity with C-reactive protein in Germany: A large nationally representative study. Chae WR, Nübel J, Baumert J, Gold SM, Otte C.
Brain Behav Immun. 2022 Jul;103:223-231. doi: 10.1016/j.bbi.2022.04.024. Epub 2022 Apr 28.
PMID: 35491003
Nejnovější komentáře